Iovance Biotherapeutics shares are trading lower after the FDA placed a clinical hold on the IOV-LUN-202 trial in response to a recently reported Grade 5 adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics' stock is trading lower following the FDA's clinical hold on the IOV-LUN-202 trial due to a Grade 5 adverse event potentially related to the trial's pre-conditioning regimen.
December 27, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Iovance Biotherapeutics' stock price is expected to face negative pressure in the short term due to the FDA's clinical hold on a key trial.
The clinical hold by the FDA on the IOV-LUN-202 trial is a significant setback for Iovance Biotherapeutics, as it directly impacts the company's clinical progress and potential future revenues. The Grade 5 adverse event raises concerns about the safety of the trial's regimen, which could lead to delays, additional costs, and a potential reevaluation of the drug's viability. This news is likely to shake investor confidence and negatively affect the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100